Curacyte scientists discover new anti-tumor agents
Curacyte scientists discover new anti-tumor agents
MUNICH, GERMANY, June 17, 2003 -- Curacyte AG, a Munich-based drug development company focused on novel treatments of inflammatory diseases, thrombotic disorders and cancer announced that its scientists have discovered a series of novel small molecule inhibitors of matriptase, a trypsin-like serine protease.
Matriptase is an important mediator in the degradation of the extracellular matrix, a process which plays a key role during metastasis. Inhibiting this key enzyme produced by tumor cells might provide a route to prevent tumor metastasis and invasive growth. This compound series thus offers potential as novel anti-tumor agents for the treatment of metastatic malignancies and Curacyte will now move this program into pre-clinical development.
Since the discovery of the gene in 1999, matriptase has increasingly gained attention as a potential biological target for inhibiting tumor spread. Today, matriptase is recognized as an innovative anti-cancer target. In in vitro assays, the Curacyte inhibitor series exhibit excellent affinity and selectivity towards the target and a pharmacokinetic profile that supports their use as pharmaceutically active substances.
Dr. Helmut Giersiefen, Chief Executive Officer of Curacyte AG, commented on the recent scientific success: "The discovery of the matriptase inhibitors corroborates the validity and value of our protease technology. Based on our proprietary inhibitor libraries and our competence with respect to the chemistry of these substances, we have identified a series of novel potential anti-tumor agents, enabling us to move another important project into preclinical development.
"We will continue to derive therapeutically valuable applications from our protease technology that we can leverage with pharmaceutical partners."
Curacyte pursues the development of its protease technology in close collaboration with the Center of Vascular Biology and Medicine of the University of Jena (Germany) under the leadership of Dr. Jörg Stürzebecher, a well-known pioneer in the area of synthetic inhibitors of serine proteases.
Source: Curacyte AG
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
